Answers · Audits & Portfolio Pruning
Our patents no longer map to our products. What do we do with them?
Updated June 2026
The short answer
You have five realistic options: license them, sell them, donate them, let them lapse, or hold them defensively. The honest economics: patents that sell at all commonly trade in the five to low six figures per asset, brokered sales commonly take 6 to 12 months, and donation rarely produces meaningful tax benefit under rules tightened in 2004.
Before choosing, check one thing: claims that no longer cover your products may still cover someone else's. That single question separates the orphans worth monetizing from the ones worth releasing.
Options for patents that no longer map to products
| Option | When it makes sense, and the economics |
|---|---|
| License | Claims read on active products elsewhere. Recurring revenue; needs evidence-of-use analysis and counsel for any assertion posture. |
| Sell | Identifiable buyers exist. Typically five to low six figures per asset when a sale happens at all; commissions commonly 25 to 35 percent; 6 to 12 months. |
| Donate | A recipient genuinely wants the technology. Tax benefit is limited under post-2004 rules and requires a qualified appraisal; rarely the economic winner. |
| Lapse | True orphans with no external relevance. Free, final, and releases the invention to the public domain. |
| Hold defensively | The technology could matter again or block a rival. Pure option value; price it against roughly $8,000 per asset at the third US fee stage plus annuities. |
First, confirm they are actually orphans
A patent that stopped mapping to your products did not necessarily stop mapping to the market. Technologies you exited may now be standard practice for competitors or thriving in an adjacent industry you never sold into. The screen is an evidence-of-use style analysis: read the claims against shipping products, starting with the companies whose later patents cite yours, since forward citations are a reasonable proxy for who built on the same ground.
The result sorts the portfolio into two very different conversations. Claims that read on active products support licensing or a premium sale, and any assertion-flavored path runs through your patent counsel, since infringement analysis and enforcement are legal work. Claims that read on nothing current are true orphans, and the goal becomes minimizing carrying cost gracefully.
The five options and their economics
Licensing preserves ownership and produces recurring revenue, but only works where the evidence-of-use screen found someone practicing the claims; expect a real program, not a mailing campaign. Selling converts the asset to cash once: realistic for patents with identifiable buyers, with broker commissions commonly running 25 to 35 percent of a sale price that is itself usually modest. Donation to a university or nonprofit sounds appealing and rarely pencils: a qualified appraisal is required and the deductible amount is sharply limited under post-2004 US tax rules, so treat it as a tax-advisor conversation. Lapsing is free and final, the right answer for true orphans, and it is what published analyses suggest happens to more than half of US patents eventually anyway. Defensive holding, paying fees to keep the asset out of hostile hands or to preserve a return path into the technology, is legitimate option value, but price it honestly: roughly $8,000 per asset at the third US fee window for a large entity, plus foreign annuities.
Sequencing beats deliberation here. Run the evidence-of-use screen 12 months before the next major fee window, market the sellable assets during that year, and let the window itself execute the lapse decisions for whatever found no taker.
Related questions
How do we find potential buyers or licensees?
Start with forward citations: companies whose patents cite yours are practicing nearby. Add competitors in the exited product line and players in adjacent industries using the same technical approach. Brokers widen the search for a commission; direct outreach works when the citation analysis points somewhere specific.
What is a realistic sale price?
Published broker data suggests most individual patents that sell trade in the five to low six figures, with packages around proven evidence of use commanding more. Patents with no identifiable user often find no buyer at any price, which is information too.
Is holding patents defensively just sunk-cost thinking?
Sometimes, which is why it needs a named rationale: a specific competitor it blocks, a specific return path it preserves, or a specific negotiation where it is leverage. A defensive rationale that cannot name its scenario is a lapse candidate with better marketing.
Could these patents come back into relevance?
Occasionally, and the cheap insurance is selective: keep the one or two families with the broadest claims in the area and release the rest. Paying full freight on an entire orphaned portfolio for optionality is how carrying costs quietly double.
Find out who else needs what you built
An evidence-of-use screen tells you which orphaned patents are assets and which are expenses. We can scope one in a free discovery call.
Talk with Our TeamRelated
ipCapital Group is a consultancy, not a law firm, and nothing on this page is legal advice. Dollar figures on this page are typical market ranges for professional IP services, drawn from published sources and industry experience across a variety of providers. They are not an ipCG quote or rate card; every ipCG engagement is individually scoped and priced. See how our pricing works.